selected scholarly activity
-
chapters
- Haemopoietic Stem Cell Processing and Storage. 519-530. 2022
- Haemopoietic Stem Cell Processing and Storage. 455-465. 2017
- Haemopoietic Stem Cell Processing and Storage. 443-454. 2013
- Dendritic Cell-Based Cancer Vaccines: Practical Considerations. 107-126. 2011
- Healing Waters Therapeutic Landscapes in Historic and Contemporary Ireland Conclusion. 175-184. 2010
- Healing Waters Therapeutic Landscapes in Historic and Contemporary Ireland Introduction. 1-18. 2010
- Healing Waters Therapeutic Landscapes in Historic and Contemporary Ireland Preface. XI-+. 2010
- Holy Wells: The Faith Cure. 19-47. 2010
- Sea Bathing: The Thalassic Cure. 111-142. 2010
- Spa Towns: The Rest Cure. 49-78. 2010
- The Modern Spa: The Relaxation Cure. 143-173. 2010
- Turkish Baths and Sweat-houses: The Sweating Cure. 79-110. 2010
-
conferences
- Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. Blood. 3496-3496. 2023
- Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. Blood. 3497-3497. 2023
- Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 1584-1587. 2022
- Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. Blood. 429-429. 2021
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy iN Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. Bone Marrow Transplantation. 48-51. 2020
- Novel Single Panel Method for Minimal Residual Disease Detection for Plasma Cells By Flow Cytometry. Blood. 6-7. 2020
- Correlation of Bridging Therapy (BT) and Lymphodepleting Chemotherapy (LDC) with clinical outcomes in patients (pts) with relapsed/refractory Diffuse Large B-cell Lymphoma (r/r DLBCL) treated with tisagenlecleucel. Oncology Research and Treatment. 62-63. 2020
- Correlative analyses of patient and clinical characteristics associated with efficacy in tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma patients in the JULIET trial. Oncology Research and Treatment. 58-58. 2020
- Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. Blood. 2883-2883. 2019
- Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. Blood. 4103-4103. 2019
- Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). Blood. 242-242. 2019
- Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial. Blood. 875-875. 2019
- Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients. Clinical Lymphoma, Myeloma and Leukemia. S251-S252. 2019
- Long-Term Follow-up of Tisagenlecleucel in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study. Transplantation and Cellular Therapy. S20-S21. 2019
- Prolonged Improvement in Patient Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL): 19-Month Follow-up (FU) of the Juliet Study. Transplantation and Cellular Therapy. S181-S182. 2019
- FACTs Fabry gene therapy clinical trial: Two-year data. Molecular Genetics and Metabolism. S99-S99. 2019
- Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL). Oncology Research and Treatment. 238-238. 2019
- Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. Blood. 1684-1684. 2018
- Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD. Bone Marrow Transplantation. 1263-1269. 2018
- Anti-thymocyte globulin (ATG) in patients with haematological malignancies undergoing haematopoietic cell transplantation (HCT) from unrelated donors: Follow up of a CBMTG randomized trial. Bone Marrow Transplantation. 395-396. 2018
- Patient-Reported Quality of Life (QoL) Following Tisagenlecleucel Infusion in Adult Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Bone Marrow Transplantation. 177-178. 2018
- REACH-3 trial design: A Phase 3, Randomized Study to Assess Ruxolitinib over BAT in Patients with Corticosteroid-Refractory Chronic Graft-versus-Host Disease Post Allo-HSCT. Bone Marrow Transplantation. 444-446. 2018
- Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Cancer Research. CT110-CT110. 2018
- Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.. Journal of Clinical Oncology. 3044-3044. 2018
- Evaluation of Subcutaneous Rituximab Administration Impacts on Canadian Systemic Therapy Suites. Value in Health. S250-S250. 2018
- Study Design of a Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate Ruxolitinib Over BAT in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation (REACH-3). Transplantation and Cellular Therapy. S208-S208. 2018
- An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Oncology Research and Treatment. 36-37. 2018
- Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2017
- Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 2017
- Primary Analysis of Juliet: A Global, Pivotal, Phase 2 Trial of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 2017
- Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood. 1679-1682. 2017
- Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis. Clinical Lymphoma, Myeloma and Leukemia. S373-S374. 2017
- GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA - AN INTERIM ANALYSIS. Clinical Lymphoma, Myeloma and Leukemia. 2017
- Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Improve Event-Free Survival (GRFS) and Overall Survival in a T-Cell Depleted Haploidentical HSCT: Phase 2 Trial in Patients with AML and ALL. Blood. 1226-1226. 2016
- Phase II Clinical Trial of Allodepleted T Cell Immunotherapy (ATIR101) Post-Transplant Results in Decreased Transplant-Related Mortality and Improved Survival in Acute Leukemia Patients Undergoing T-Depleted Haploidentical Stem Cell Transplantation. Cytotherapy. S15-S15. 2016
- Carmustine-Free Conditioning Regimens Offer Comparable Efficacy to BEAM: The First Report of the Canadian Blood and Marrow Transplant Group Registry. Transplantation and Cellular Therapy. S37-S38. 2016
- Donor lymphocytes depleted of alloreactive T-cells (ATIR101) improve overall survival and reduce transplant related mortality in a T-cell depleted haploidentical HSCT: Results from a Phase 2 trial in patients with AML and ALL. Bone Marrow Transplantation. S27-S28. 2016
- Absence of Viral Complications When Using Rituximab to Treat TTP with Plasma Exchange. Blood. 2261-2261. 2015
- Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen. Blood. 4391-4391. 2015
- A Phase II Study Evaluating the Efficacy of Rituximab in the Management of Patients with Relapsed or Refractory TTP. Blood. 4191-4191. 2014
- Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. Blood. 2014
- Thymoglobulin Decreases the Need for Immunosuppression at 12 Months after Myeloablative and Nonmyeloablative Unrelated Donor Transplantation: CBMTG 0801, a Randomized, Controlled Trial. Blood. 38-38. 2014
- Towards a clinical trial of lentivirus-mediated gene therapy for Fabry disease: In vitro patient cell mobilization and transduction outcomes. Clinical Biochemistry. 151-151. 2014
- Pre-Clinical Patient Cell Mobilizations and Transduction Outcomes in Preparation for a Clinical Trial Application of Lentivirus-Mediated Gene Therapy for Fabry Disease. Molecular Therapy. S140-S140. 2014
- Immunotherapy with donor lymphocytes depleted of anti-host reactive cells results in safe and efficacious haploidentical HSCT: interim results from a phase II trial in patients with hematologic malignancies. Cytotherapy. S27-S27. 2014
- CD34 CELL DOSE IS CORRELATED WITH HEMATOLOGIC RECOVERY BUT NOT CHRONIC GVHD: RESULTS OF THE CBMTG TRIAL COMPARING G-CSF-MOBILIZED PERIPHERAL BLOOD(G-PB) VS G-CSF STIMULATED BONE MARROW(G-BM) IN SIBLING ALLOGRAFTS FOR HEMATOLOGIC MALIGNANCIES. Bone Marrow Transplantation. S55-S56. 2014
- DONOR B CELLS POPULATIONS, IFNG-PRODUCING T CELLS, AND CD56BRIGHT NK CELLS CORRELATE WITH DEVELOPMENT OF CHRONIC GVHD IN G-CSF STIMULATED SIBLING DONOR PERIPHERAL BLOOD AND BONE MARROW: RESULTS FROM THE CANADIAN BMT GROUP 0601 RANDOMIZED, PHASE III TRIAL. Bone Marrow Transplantation. S299-S299. 2014
- SELECTIVE PHOTODEPLETION OF RECIPIENT-ALLOREACTIVE T-CELLS ENABLES SAFE AND EFFICACIOUS HAPLOIDENTICAL HSCT: INTERIM RESULTS FROM A PHASE II TRIAL IN PATIENTS WITH AML, ALL, AND MDS. Bone Marrow Transplantation. S221-S221. 2014
- Vaccination with autologous dendritic cells pulsed with a MUC1 glycopeptide: a phase I/II study in castrate resistant non-metastatic prostate cancer patients. Cytotherapy. S39-S39. 2013
- Gene therapy for Fabry disease patients: The importance of efficient biomarker monitoring. Molecular Genetics and Metabolism. S21-S21. 2013
- Higher Proportions of IFNg-Producing T Cells, CD56bright NK Cells and Immature B Cells in the Lymphocytes of G-CSF Stimulated Donor Grafts Are Associated with Less Chronic Gvhd After HSCT: Results From the Canadian BMT Group 0601 Randomized, Phase III Trial. Blood. 1944-1944. 2012
- Abstract A16: A phase I/II clinical trial of a MUC1-glycopeptide dendritic cell vaccine in castrate resistant non-metastatic prostate cancer patients. Cancer Research. A16-A16. 2012
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non-Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 917-917. 2011
- AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR TRANSFORMED INDOLENT NON-HODGKIN LYMPHOMA: A REPORT OF THE CANADIAN BLOOD AND MARROW TRANSPLANT GROUP (CBMTG). Annals of Oncology. 115-115. 2011
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy. Blood. 566-566. 2009
- Generation and Implementation of a Novel Murine Xenograft Model for Evaluating Human Hematopoietic Cell-Targeted Gene Therapies for Fabry Disease.. Blood. 1385-1386. 2009
- Use of MGMT Resistance to Enrich for Transduced Hematopoietic Cells in Gene Therapy for Fabry Disease. Blood. 1388-1388. 2009
- Determining Patterns of Therapy Choice in Patients Treated for Early Stage, Aggressive Histology Non-Hodgkin's Lymphoma. International Journal of Radiation Oncology Biology Physics. S484-S485. 2009
- 17 DETERMINING PATTERNS OF THERAPY CHOICE IN PATIENTS TREATED FOR EARLY STAGE, AGGRESSIVE HISTOLOGY NONHODGKIN'S LYMPHOMA. Radiotherapy and Oncology. S6-S6. 2009
- Synthesis and catalytic activity of Bis-diimidazolylidine complexes of nickel. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2009
- A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura. Kidney International, Supplement. S55-S58. 2009
- INOR 390-Iminoisoindoline-ligated palladacycles: Synthesis and catalytic activity for C-C bond forming reactions. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2008
- INOR 648-Synthesis of nonsymmetrically substituted chelating bis-NHC Palladium(II) complexes for C-C and C-X coupling reactions. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2008
- INOR 764-Investigations into homogeneous copper(II) systems for ethylene polymerization. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2008
- Outcomes of reduced-intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma - national review of the Canadian experience by the Canadian Blood and Marrow Transplant Group. Bone Marrow Transplantation. S250-S250. 2008
- A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).. Blood. 908-908. 2007
- ADAMTS-13 Levels Do Not Predict Outcome in Thrombotic Thrombocytopenic Purpura: Protein S Levels Are Maintained during Plasma Exchange with Solvent Detergent Treated Plasma.. Blood. 2895-2895. 2007
- INOR 48-Palladacycles vs. chelating N-heterocyclic carbene complexes of nickel as catalysts for C-C bond forming reactions. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. 2007
- Large-Scale Production of Autologous CD14+-Monocyte Derived Dendritic Cells Co-Electroporated with Amplified Total Tumour mRNA and Human CD40L mRNA in Patients with B-Cell Chronic Lymphocytic Leukemia.. Blood. 3720-3720. 2006
- 316. Production of Adenoviral Vectors in an Academic cGMP Facility. Molecular Therapy. S121-S121. 2006
- The Effect of Prophylactic Administration of Myeloid Growth Factors Following Autologous Stem Cell Transplantation for Patients with Hematological Malignancies: A Systematic Review.. Blood. 2192-2192. 2004
- Canadian pilot trial of haploidentical donor transplantation.. Blood Cells, Molecules, and Diseases. 181-182. 2004
- Canadian pilot trial of haplo-identical donor transplantation. Transplantation and Cellular Therapy. 38-38. 2004
- Induction of specific immunity to B-CLL cells by in vitro stimulation using antigen pulsed autologous dendritic cells.. Blood. 439A-439A. 2003
- The ability to harvest increased numbers of peripheral blood progenitor cells is a predictor of improved overall survival in patients with multiple myeloma treated by autologous hematopoietic stem cell transplantation. Blood. 983A-983A. 2003
- Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. Leukemia and Lymphoma. 39-48. 2003
- Reactivity of vinyl chloride with single-site olefin polymerization catalysts.. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. A66-A66. 2002
- Canadian bone marrow transplant group (CBMTG) will use modified perugia protocol for multi-centre pilot study of haplo-identical transplantation. Leukemia. 416-416. 2002
- The combined effect of all trans retinoic acid and the glucocorticoid, budesonide, on eosinophil differentiation from cord blood-derived CD34+ progenitor cells in vitro. Journal of Allergy and Clinical Immunology. S166-S166. 2002
- Bone marrow derived dendritic cell vaccination of spontaneous canine melanoma using human gp100 antigen. Clinical and immunological findings.. Blood. 698A-698A. 2001
- Patients with severe sepsis vary markedly in their ability to generate activated protein C.. Blood. 445A-445A. 2001
- Reactions of vinyl chloride with single-site ethylene polymerization catalysts.. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY. U612-U612. 2001
- The effect of the glucocorticoid, budesonide, on eosinophil differentiation from bone marrow CD34(+) progenitors in vitro. Journal of Allergy and Clinical Immunology. S176-S176. 2001
- Upregulation of eotaxin receptor, CCR3, on bone marrow CD34+progenitor cells following allergen-inhalation challenge in asthmatic subjects: A mechanism of progenitor cell egress from the bone marrow during allergic inflammation. Journal of Allergy and Clinical Immunology. S324-S324. 2001
- A strategy of peripheral blood stem cell transplantation is cost-effective compared to melphalan and prednisone in younger patients with multiple myeloma.. Blood. 846A-846A. 2000
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: Are trial results generalized to other patient populations?. Blood. 132A-132A. 2000
- Patients with multiple myeloma transplanted with increased numbers of PBPC demonstrate early recovery of total lymphocytes.. Blood. 335B-335B. 2000
- 227 Glucocorticoid enhancement of IL-5-induced bone marrow eosinophil progenitor colony formation in vitro. Journal of Allergy and Clinical Immunology. S74-S74. 2000
- 521 Increased numbers of eosinophil progenitor cells (CD34+IL5R?+) in the bone marrow of atopic asthmatic subjects. Journal of Allergy and Clinical Immunology. S172-S172. 2000
- Adenoviral-based gene transfer in a murine model of chronic lymphocytic leukemia.. Blood. 314A-314A. 1999
- Optimum timing of apheresis following rHuGCSF and rmetHuSCF in multiple myeloma: A temporal analysis of CD34 absolute counts and subsets.. Blood. 554A-554A. 1999
- The preferences of traditional quality of life domains are similar in older versus younger patients with non-Hodgkin's lymphoma.. Blood. 185A-185A. 1999
- CD34+ t(15;17) APL represents a distinct subgroup associated with CD2+, bcr3 isoform, microgranular morphology, a high white count and a poor prognosis.. Blood. 604A-604A. 1998
- Loss of CD34(+)/CD38(-) cells during ex vivo expansion of purified CD34(+) stem cells using adenoviral-based gene transfer of stem cell factor to bone marrow stromal cells.. Blood. 151A-151A. 1998
- The entity of CD34+ t (15; 17) acute promyelocytic leukemia. British Journal of Haematology. 100-100. 1998
- First 100 donors in the Canadian bone marrow transplant group trial comparing peripheral blood (PB) and bone marrow (BM) in allogeneic transplant.. Bone Marrow Transplantation. S36-S36. 1998
- Adenoviral-based gene transfer of two forms of stem cell factor to human bone marrow stromal cells.. Blood. 4609-4609. 1997
- Intramarrow administration of an adenoviral vector expressing canine GM-CSF to alleviate neutropenia in dogs treated with chemotherapy.. Blood. 1062-1062. 1997
- Isolation and characterization of cultured human dendritic cells: A potential target for adenoviral-based gene transfer of tumour peptides.. Blood. 4636-4636. 1997
- Inhaled allergen-induced changes in bone marrow eosinophil/basophil progenitors in mild asthmatic subjects.. Journal of Allergy and Clinical Immunology. 1485-1485. 1997
- Monitoring interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation: A marker of acute graft-versus-host disease. Blood. 1675-1675. 1996
- Adenovirus‐Vector‐Mediated Cytokine Gene Transfer to Lung Tissuea. Annals of the New York Academy of Sciences. 235-244. 1996
- ADENOVIRUS VECTOR CYTOKINE GENE-TRANSFER TO LUNG-TISSUE. Journal of Cellular Biochemistry. 377-377. 1995
- ADENOVIRUS VECTOR CYTOKINE GENE-TRANSFER TO LUNG-TISSUE. The FASEB Journal. A858-A858. 1995
- EFFECTIVE CYTOKINE GENE-TRANSFER TO BONE-MARROW STROMAL CELLS USING ADENOVIRAL VECTORS. Journal of Cellular Biochemistry. 406-406. 1995
- EFFECTIVE CYTOKINE GENE-TRANSFER IN HUMAN LONG-TERM BONE-MARROW CULTURED-CELLS USING ADENOVIRAL VECTORS. Blood. A740-A740. 1994
- Trends in autologous hematopoietic stem cell transplant in older patients with Multiple Myeloma 2000-2017: The Canadian Experience
-
journal articles
- Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy. BMC Cancer. 24:984. 2024
- Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example. Oncology and Therapy. 12:239-245. 2024
- Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clinical Lymphoma, Myeloma and Leukemia. 24:e227-e234. 2024
- Identification of cells of leukemic stem cell origin with non-canonical regenerative properties. Cell Reports Medicine. 5:101485-101485. 2024
- Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting. Transplantation and Cellular Therapy. 30:S187-S188. 2024
- Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. Transplantation and Cellular Therapy. 30:S189-S190. 2024
- LSD1 Inhibition Synergizes with Venetoclax in Acute Myeloid Leukemia By Targeting Cellular Metabolism. Blood. 142:4156-4156. 2023
- Treatment Patterns and Healthcare Resource Utilization Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Blood. 142:3774-3774. 2023
- Leukemic progenitor compartment serves as a prognostic measure of cancer stemness in patients with acute myeloid leukemia. Cell Reports Medicine. 4:101108-101108. 2023
- Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease. Molecular Therapy - Methods and Clinical Development. 28:262-271. 2023
- Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphomas. Blood. 140:8036-8037. 2022
- Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. 6:4816-4820. 2022
- Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders. EMBO Molecular Medicine. 14:e14297. 2022
- An Overview of Modified Chitosan Adsorbents for the Removal of Precious Metals Species from Aqueous Media. Molecules. 27:978-978. 2022
- Automated bone marrow cytology using deep learning to generate a histogram of cell types. Communications Medicine. 2:45. 2022
- Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Advances. 5:4980-4991. 2021
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology. 22:1403-1415. 2021
- Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma. Cytotherapy. 23:820-832. 2021
- Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid- Refractory or Dependent Chronic GVHD – a Multicentre Phase II Clinical Trial (CARE Trial). Transplantation and Cellular Therapy. 27:S285-S285. 2021
- Lentivirus-mediated gene therapy for Fabry disease. Nature Communications. 12:1178. 2021
- Abnormal dopamine receptor signaling allows selective therapeutic targeting of neoplastic progenitors in AML patients. Cell Reports Medicine. 2:100202-100202. 2021
- Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations. Current Oncology. 27:270-274. 2020
- Canadian Perspective on Managing Multiple Myeloma during the COVID-19 Pandemic: Lessons Learned and Future Considerations.. Current Oncology. 27:270-274. 2020
- Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. Blood Advances. 4:629-637. 2020
- Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Advances. 4:560-572. 2020
- Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology. 7:e100-e111. 2020
- Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology. 11:93-99. 2020
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. New England Journal of Medicine. 380:45-56. 2019
- Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites. Current Oncology. 25:300-306. 2018
- Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Cancer Cell. 34:483-498.e5. 2018
- A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances. 2:1935-1945. 2018
- Plerixafor effectively mobilizes CD56bright NK cells in blood, providing an allograft predicted to protect against GVHD. Blood. 131:2863-2866. 2018
- Forgiveness, spirituality and love: thematic analysis of last statements from Death Row, Texas (2002–17). QJM - Monthly Journal of the Association of Physicians. 111:399-403. 2018
- Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nature Cell Biology. 19:1336-1347. 2017
- CD56 bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft- versus -host disease: the Canadian Blood and Marrow Transplant Group randomized 0601 study results. Hematology Journal. 102:1936-1946. 2017
- How we treat thrombotic thrombocytopenic purpura: Results of a Canadian TTP practice survey. Journal of Clinical Apheresis. 32:246-256. 2017
- The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma. Transfusion and Apheresis Science. 56:552-557. 2017
- Sam68 Allows Selective Targeting of Human Cancer Stem Cells. Cell Chemical Biology. 24:833-844.e9. 2017
- GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS. Hematological Oncology. 35:27-27. 2017
- Lentivector Iterations and Pre-Clinical Scale-Up/Toxicity Testing: Targeting Mobilized CD34 + Cells for Correction of Fabry Disease. Molecular Therapy - Methods and Clinical Development. 5:241-258. 2017
- Erratum to “Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study” [Biol Blood Marrow Transplant 2016;22:1410-1415]. Transplantation and Cellular Therapy. 23:534-534. 2017
- TTP: One of the TMA’s—How to sort it out. Transfusion and Apheresis Science. 56:57-58. 2017
- Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer. Cancer immunology research. 4:881-892. 2016
- Transfusion‐related alloimmunization in children: epidemiology and effects of chemotherapy. Vox Sanguinis. 111:299-307. 2016
- Filgrastim-Stimulated Bone Marrow Compared with Filgrastim-Mobilized Peripheral Blood in Myeloablative Sibling Allografting for Patients with Hematologic Malignancies: A Randomized Canadian Blood and Marrow Transplant Group Study. Transplantation and Cellular Therapy. 22:1410-1415. 2016
- Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. The Lancet Oncology. 17:164-173. 2016
- A phase‐II sequential case‐series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. British Journal of Haematology. 170:208-217. 2015
- Cellular Reprogramming Allows Generation of Autologous Hematopoietic Progenitors From AML Patients That Are Devoid of Patient-Specific Genomic Aberrations. Stem Cells. 33:1839-1849. 2015
- Selective Photodepletion of Recipient-Alloreactive T-Cells Enables Safe and Efficacious Haploidentical HSCT: Initial Results from a Phase 2 Trial in Patients with AML, ALL, and MDS. Blood. 124:314-314. 2014
- Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. Transplantation and Cellular Therapy. 20:1813-1818. 2014
- Niche displacement of human leukemic stem cells uniquely allows their competitive replacement with healthy HSPCs. Journal of Experimental Medicine (JEM). 211:1925-1935. 2014
- Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies. World Journal of Stem Cells. 6:380-380. 2014
- Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. Frontiers in Immunology. 5:191. 2014
- A Canadian Blood and Marrow Transplant Group (CBMTG) Randomised Trial Comparing G-CSF Mobilized Peripheral Blood Versus G-CSF Stimulated Bone Marrow In Recipients Of Sibling Allografts For Hematologic Malignancies. Blood. 122:709-709. 2013
- A Human Type 5 Adenovirus–Based Tuberculosis Vaccine Induces Robust T Cell Responses in Humans Despite Preexisting Anti-Adenovirus Immunity. Science Translational Medicine. 5:205ra134. 2013
- Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. Journal of Clinical Oncology. 31:1164-1171. 2013
- Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes. Gene Therapy. 20:24-34. 2013
- Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem Cells. Cell. 149:1284-1297. 2012
- Cellular MRI as a suitable, sensitive non-invasive modality for correlating in vivo migratory efficiencies of different dendritic cell populations with subsequent immunological outcomes. International Immunology. 24:29-41. 2012
- Comparison of Comorbidity Scores and the Impact of Comorbidities on Length of Stay and Survival in Patients with Non−Hodgkin's Lymphoma Treated with Autologous Stem Cell Transplant. Blood. 118:2091-2091. 2011
- Cellular magnetic resonance imaging of monocyte-derived dendritic cell migration from healthy donors and cancer patients as assessed in a scid mouse model. Cytotherapy. 13:1234-1248. 2011
- Induction of specific human cytotoxic T cells using dendritic cells transduced with an adenovector encoding rat epidermal growth factor receptor 2. International Journal of Oncology. 39:907-913. 2011
- Labelling dendritic cells with SPIO has implications for their subsequent in vivo migration as assessed with cellular MRI. Contrast Media and Molecular Imaging. 6:314-327. 2011
- Outcomes of reduced-intensity conditioning allo-SCT for Hodgkin's lymphoma: a national review by the Canadian Blood and Marrow Transplant Group. Bone Marrow Transplantation. 45:1253-1255. 2010
- Empiric Antifungal Therapy with Amphotericin B in the Era of Fluconazole Prophylaxis: a Cohort Study in Adults with Acute Myeloid Leukemia Treated within An Institutional Antifungal Policy.. Blood. 114:1390-1390. 2009
- Generation and Implementation of a Novel Murine Xenograft Model for Evaluating Human Hematopoietic Cell-Targeted Gene Therapies for Fabry Disease.. Blood. 114:3576-3576. 2009
- Use of MGMT Resistance to Enrich for Transduced Hematopoietic Cells in Gene Therapy for Fabry Disease.. Blood. 114:3584-3584. 2009
- Characterizing Complex Polysera Produced by Antigen-Specific Immunization through the Use of Affinity-Selected Mimotopes. PLoS ONE. 4:e5309-e5309. 2009
- Analysis of the Clinical Impact of the Use of Palifermin in Patients Undergoing Autologous Peripheral Blood Progenitor Cell Transplantation for Multiple Myeloma and Relapsed Lymphoma. Blood. 112:4332-4332. 2008
- In Vitro Effects of Budesonide on Eosinophil-Basophil Lineage Commitment~!2008-03-03~!2008-05-27~!2008-06-13~!. Open Respiratory Medicine Journal. 2:60-66. 2008
- Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies. Oncogene. 27:208-217. 2008
- Immuno-gene therapy approaches for cancer: from in vitro studies to clinical trials. Frontiers in Bioscience - Landmark. Volume:3202-3202. 2008
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. Transplantation and Cellular Therapy. 12:491-505. 2006
- Generation ofin vitroB-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate. Leukemia and Lymphoma. 47:297-306. 2006
- Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells. Hematology. 10:189-203. 2005
- Autologous peripheral blood progenitor cells are a potential source of parvovirus B19 infection. Transfusion. 45:394-398. 2005
- Progenitor egress from the bone marrow after allergen challenge: Role of stromal cell–derived factor 1α and eotaxin. Journal of Allergy and Clinical Immunology. 115:501-507. 2005
- Bone Marrow‐Derived Dendritic Cell Vaccination of Dogs with Naturally Occurring Melanoma by Using Human gp100 Antigen. Journal of Veterinary Internal Medicine (JVIM). 19:56-63. 2005
- Bone Marrow–Derived Dendritic Cell Vaccination of Dogs with Naturally Occurring Melanoma by Using Human gp100 Antigen. Journal of Veterinary Internal Medicine (JVIM). 19:56-56. 2005
- An Evaluation of Age-related Differences in Quality of Life Preferences in Patients with Non-Hodgkin's Lymphoma. Leukemia and Lymphoma. 45:2471-2476. 2004
- Canadian multicenter pilot trial of haploidentical donor transplantation. Blood Cells, Molecules, and Diseases. 33:222-226. 2004
- Kinetics of Bone Marrow Eosinophilopoiesis and Associated Cytokines after Allergen Inhalation. American Journal of Respiratory and Critical Care Medicine. 169:565-572. 2004
- Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein. Blood. 103:93-99. 2004
- Allergen‐induced fluctuation in CC chemokine receptor 3 expression on bone marrow CD34+ cells from asthmatic subjects: significance for mobilization of haemopoietic progenitor cells in allergic inflammation. Immunology. 109:536-546. 2003
- Budesonide enhancement of eosinophil differentiation in vitro does not involved IL-5Rα overexperesion or increased p38 MAP kinase activation. Journal of Allergy and Clinical Immunology. 111:S266-S266. 2003
- Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma. Leukemia and Lymphoma. 44:29-37. 2003
- Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34+ absolute counts and subsets. Bone Marrow Transplantation. 30:851-860. 2002
- Allergen-induced Increases in Bone Marrow T Lymphocytes and Interleukin-5 Expression in Subjects with Asthma. American Journal of Respiratory and Critical Care Medicine. 166:883-889. 2002
- Functional analysis of human hematopoietic repopulating cells mobilized with granulocyte colony-stimulating factor alone versus granulocyte colony-stimulating factor in combination with stem cell factor. Blood. 100:869-878. 2002
- The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. Journal of Allergy and Clinical Immunology. 110:96-101. 2002
- Genetically modified dendritic cells in cancer therapy: Implications for transfusion medicine. Transfusion Medicine Reviews. 15:292-304. 2001
- Circulating hematopoietic stem cells serve as novel targets for in utero gene therapy. The FASEB Journal. 15:1628-1630. 2001
- Circulating hematopoietic stem cells serve as novel targets for in utero gene therapy.. The FASEB Journal. 15:1628-1630. 2001
- CD34‐positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform. American Journal of Hematology. 67:34-41. 2001
- Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Therapy. 8:316-323. 2001
- Assessment of clinical trial inclusion criteria to a cohort of lymphoma patients undergoing autologous transplantation: are trial results generalized to other patient populations?. Blood. 96. 2000
- Characterization of Chemokine Receptors Expressed in Primitive Blood Cells During Human Hematopoietic Ontogeny. Stem Cells. 18:374-381. 2000
- Enhanced Immune Response to the Melanoma Antigen gp100 Using Recombinant Adenovirus-Transduced Dendritic Cells. Cellular Immunology. 198:131-138. 1999
- An Inhaled Corticosteroid, Budesonide, Reduces Baseline but Not Allergen-induced Increases in Bone Marrow Inflammatory Cell Progenitors in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine. 159:1457-1463. 1999
- An inhaled corticosteroid, budesonide, reduces baseline but not allergen-induced increases in bone marrow inflammatory cell progenitors in asthmatic subjects. American Journal of Respiratory and Critical Care Medicine. 159:1457-1463. 1999
- Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression.. International Journal of Oncology. 14:771-776. 1999
- Humanised antibodies for cancer therapy. Part 2: Review of clinical trials with rituximab and trastuzumab. Current Oncology. 6:131-137. 1999
- Clinical and economic analysis of allogeneic peripheral blood progenitor cell transplants: a Canadian perspective. Bone Marrow Transplantation. 22:1199-1205. 1998
- . Transfusion Medicine Reviews. 12:303-304. 1998
- PML/RARα APL with undifferentiated morphology and stem cell immunophenotype. Leukemia. 12:1492-1493. 1998
- The Canadian Experience Using Plasma Exchange for Immune Thrombocytopenic Purpura. Transfusion and Apheresis Science. 19:295-300. 1998
- Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation. Bone Marrow Transplantation. 21:769-773. 1998
- Changes in Bone Marrow Inflammatory Cell Progenitors after Inhaled Allergen in Asthmatic Subjects. American Journal of Respiratory and Critical Care Medicine. 157:99-105. 1998
- Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation.. Journal of Clinical Investigation. 100:2466-2475. 1997
- Transient Gene Transfer and Expression in the Lung. Chest. 111:89S-94S. 1997
- Intramarrow Cytokine Gene Transfer by Adenoviral Vectors in Dogs. Human gene therapy. Clinical development. 8:545-553. 1997
- Adenoviral gene transfer of macrophage inflammatory protein-2 in rat lung.. American Journal of Pathology. 149:1395-1403. 1996
- Recombinant Human Adenovirus with Rat MIP‐2 Gene Insertion Causes Prolonged PMN Recruitment to the Murine Brain. European Journal of Neuroscience. 8:1803-1811. 1996
- Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM-CSF in pulmonary inflammation. Journal of Leukocyte Biology. 59:481-488. 1996
-
preprints
- Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy 2023
- Histogram of Cell Types: Deep Learning for Automated Bone Marrow Cytology 2021
- Anti-Thymocyte Globulin for Patients Undergoing Hematopoietic Cell Transplantation from Unrelated Donors: A Randomized, Controlled, Open-Label, Phase 3, Multicentre Trial from Cell Therapy Transplant Canada 2019